Perpetual Ltd Purchases 36,562 Shares of Bristol Myers Squibb Company $BMY

Perpetual Ltd raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 121.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,741 shares of the biopharmaceutical company’s stock after buying an additional 36,562 shares during the quarter. Perpetual Ltd’s holdings in Bristol Myers Squibb were worth $3,600,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BMY. Gateway Investment Advisers LLC lifted its holdings in shares of Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC increased its stake in Bristol Myers Squibb by 25.9% during the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares during the last quarter. Stephens Inc. AR raised its position in Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after purchasing an additional 32,476 shares during the period. Railway Pension Investments Ltd lifted its stake in shares of Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after purchasing an additional 40,300 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its stake in shares of Bristol Myers Squibb by 110.1% in the 3rd quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock valued at $4,789,000 after purchasing an additional 55,624 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

BMY stock opened at $59.57 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The firm has a market cap of $121.63 billion, a price-to-earnings ratio of 17.27, a PEG ratio of 0.17 and a beta of 0.27. The business’s fifty day simple moving average is $59.37 and its two-hundred day simple moving average is $52.70. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Morgan Stanley restated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Citigroup lifted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $61.41.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase‑3 data for Camzyos in the SCOUT‑HCM adolescent trial could expand the label and support longer‑term revenue upside. SCOUT‑HCM Trial Results
• Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY by nominating a development candidate — near‑term cash and partner validation for BMY’s partnered R&D. Janux Milestone
• Positive Sentiment: Unusually large call‑option activity (~66,900 calls) signals speculative bullish positioning by traders anticipating upside moves. Call Option Activity
• Positive Sentiment: Analyst pieces and screens highlight BMY’s history of earnings surprises and argue the company has components that could support an earnings beat next quarter — a sentiment tailwind if results improve. Zacks Coverage
• Neutral Sentiment: Market estimates and long‑term market studies (e.g., HNSCC market growth to ~ $4.5B by 2034) provide attractive addressable‑market context but aren’t immediate catalysts. HNSCC Market Outlook
• Neutral Sentiment: Brokerage consensus remains centered on a “Hold” and the street target (~$61.41) is close to the current price — keeps upside expectations measured. Analyst Consensus
• Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at about $61.67 on April 1 (Form 4), trimming his stake ~15.9% — investors sometimes read executive sales as a near‑term negative signal. Insider Form 4
• Negative Sentiment: Sector risk: reports that the U.S. may consider heavy tariffs (up to 100%) on branded/patented drug imports sparked broad healthcare selling and pressured BMY along with peers. Tariffs / Sector Selloff
• Negative Sentiment: Recent quarterly results showed an EPS miss (Feb. 5), which keeps investor focus on near‑term profitability despite FY‑26 guidance; that remains a headwind until earnings execution improves. Earnings Recap

Insider Buying and Selling

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.